Clinical Trial Data

Clinical Trial Change Feed

Daily-detected changes across ClinicalTrials.gov records, structured and labeled by change type. Status changes, protocol amendments, endpoint modifications, enrollment shifts, and new site additions or removals.

Request dataset →

450K+ trials monitored

500+ biotech companies tracked

Daily comparison against ClinicalTrials.gov

Detected this week

Recent changes caught automatically from ClinicalTrials.gov.

Updated May 4, 2026

Novartis NVS Mar 28

NCT06031844 PHASE2 Endpoint

The primary endpoint was changed from measuring serum levels of IL-6 and IL-18 to specifically measuring the ratio to baseline serum levels of IL-18 and IL-6 for DFV890 based on an Emax model. This represents a more specific and model-driven approach to assessing the drug's effect on these biomarkers. The secondary endpoint was also refined to specify trough plasma concentration (Ctrough) at specific pre-dose time points.

AMGEN INC AMGN Mar 28

NCT04303780 PHASE3 Update

Completion date: 2026-02-25 → 2026-05-29

HUTCHMED (China) Ltd HCM Mar 28

NCT04762602 PHASE1 Update

Trial stopped: The study was terminated based on strategic evaluation of the clinical development of HMPL-306 with no safety concerns

Detailed Change Tracking Available

Trials change quietly. We don't miss it.

Daily comparison against ClinicalTrials.gov. Endpoint modifications, enrollment shifts, and status change categorized and summarized automatically.

NCT04762602

A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations

Terminated Phase 1

HUTCHMED (China) Ltd HCM

Enrollment

Primary Completion

2025-02

Detected

Mar 28, 2026

Endpoint modification detected automatically

Primary endpoint timeframe

− From the first dose of the study drug to 37 days after the last dose of study drug

+ From the first dose of study drug (Day 1) up to Day 28 of Cycle 1

Primary endpoint timeframe

− Up to 28 days after first dose of study drug

+ From the first dose of study drug (Day 1) up to Day 28 of Cycle 1

Secondary endpoint 1 timeframe

− PK weeks at screening through safety follow-up, assessed up to 36 months

+ Pre-dose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours post-dose on Day 1 of Cycles 1 and 2 for Part 1

Secondary endpoint 2 timeframe

− From first dose of study drug to the time of progressive disease, assessed up to 36 months

+ Tumor assessments performed every 8 weeks (+/-1 week) from Cycle 1 Day 1 for the first 24 weeks and every 12 weeks (+/-2 weeks) thereafter until end of treatment or end of efficacy follow-up period, approximately 47 months for Part 1

+ 5 more endpoints modified

AI Summary

A new primary endpoint, Recommended Phase 2 Dose (RP2D) of HMPL-306, was added. The primary endpoint 'Frequency and severity of AEs' was rephrased to 'Number of Patients With Treatment-Emergent Adverse Events and Treatment-Emergent Serious Adverse Events (TESAEs)' with a slightly extended timeframe. The secondary endpoint 'Clinical Benefit Rate (CBR)' was replaced with 'Disease Control Rate (DCR)' and a new secondary endpoint, 'Maximum Inhibition Rate of Plasma 2-Hydroxyglutaric Acid (2-HG)', was added. Additionally, 'Time to Response (TTR)' was added as a new secondary endpoint.

Change Detection

What gets caught.

ClinicalTrials.gov logs every update but doesn't surface them. We run a daily comparison and categorize every change.

Endpoint

Endpoint Modifications

Primary and secondary endpoint changes, outcome measures added or removed, assessment timepoints shifted.

Enrollment

Enrollment Changes

Target enrollment updated, eligibility criteria modified, new sites added, age range or inclusion/exclusion criteria changed.

Status

Status Shifts

Recruiting, suspended, terminated, completed. Caught the day the registry updates. Stopped trials flagged immediately.

Study Arm

Study Arms

Arms added or dropped, dosing changes, new intervention branches, comparator updates across multi-arm studies.

Company Pipeline View

Trials organized by company.

Every company mapped to their complete trial pipeline. Trials with recent changes flagged automatically. Sample from Solid Biosciences Inc. (SLDB).

Solid Biosciences Inc. SLDB

4 recruiting

1 Phase 3

6 trials shown

Phase 1 ● Recruiting Recently updated

A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (...

NCT07148089 · 18 enrolled

Phase 3 ● Recruiting

A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT...

NCT07160634 · 80 enrolled

Phase 1/2 ● Recruiting

A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)

NCT06138639 · 60 enrolled

Phase 1 ● Recruiting

A Study of SGT-212 Gene Therapy in Friedreich's Ataxia

NCT07180355 · 10 enrolled

Use Cases

Who Uses This Data

Structured for direct analysis. No cleaning, no manual joins required.

CROs and Site Networks

● Monitor when competing trials open new sites in your geography
● Track trial status changes that signal patient pool availability or competitive pressure
● Identify trial activity by disease or intervention type

Pharma Business Development

● Track competitor pipeline changes that signal strategic pivots or program setbacks
● Monitor endpoint modifications as early signals of program direction
● Map the active trials to identify collaborators or competition in your disease or intervention area

What's Included

Delivery and Data Fields

How It's Delivered

Source cadence: Daily sync from ClinicalTrials.gov via AACT (3:30am UTC)

Primary Sources

• ClinicalTrials.gov via AACT (NIH/NLM)
• Registered trial records
• Daily change detection across all registered sponsors

Fields Include

• NCT ID and trial title
• Change category (status, endpoint, enrollment, site, arm, date)
• Previous and current field values
• Change detection date
• Sponsor name and canonical company identifier
• Phase and MeSH condition codes
• Reported enrollment count (before/after where applicable)
• Primary completion and study completion dates
• AI-generated summaries of endpoint modifications

Get the Data